Applied DNA Receives Approximately $3.6 Million in Net Proceeds from Warrant Exercise

Author's Avatar
Aug 09, 2022

Applied+DNA+Sciences%2C+Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that it has received approximately $3.6 million in net proceeds following an exercise of Series B warrants by an institutional investor in the Company.